Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Company Deals

Leman Biotech Raises RMB 200M Series A+ – Advances Ultra‑Low‑Dose Metabolically Armored CAR‑T

Fineline Cube Mar 4, 2026
Company Deals

Teva Secures $400M Blackstone Funding for Duvakitug – TL1A Antibody Advances in IBD Phase III

Fineline Cube Mar 4, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label

Fineline Cube Mar 4, 2026
Company Drug

Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter

Fineline Cube Mar 4, 2026
Company Deals

Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform

Fineline Cube Aug 17, 2023

US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan...

Company Digital

JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report

Fineline Cube Aug 17, 2023

JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...

Company

Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law

Fineline Cube Aug 17, 2023

Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of...

Company Drug

Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis

Fineline Cube Aug 16, 2023

China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...

Company

Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom

Fineline Cube Aug 16, 2023

Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of...

Company

Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment

Fineline Cube Aug 16, 2023

Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the...

Company Drug

Yingli Pharma’s Linperlislib Receives Priority Review Status for Lymphoma Treatments

Fineline Cube Aug 16, 2023

US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US...

Company

Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending

Fineline Cube Aug 16, 2023

Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and...

Company Deals

Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal

Fineline Cube Aug 16, 2023

Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to...

Company Drug

Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept

Fineline Cube Aug 16, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory...

Company Deals

Gilead Sciences Enters Collaboration with Tentarix Biotherapeutics for Polyspecific Antibodies

Fineline Cube Aug 16, 2023

Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix...

Company Deals

Amoy Diagnostics and AstraZeneca Expand Collaboration on Companion Diagnostic Development

Fineline Cube Aug 16, 2023

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced a new cooperation agreement with...

Company Drug

YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment

Fineline Cube Aug 16, 2023

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...

Company Drug

Everest Medicines’ Partner Venatorx Pharmaceuticals Receives FDA Priority Review for Cefepime-Taniborbactam

Fineline Cube Aug 16, 2023

China-based Everest Medicines (HKG: 1952) announced that its partner, Venatorx Pharmaceuticals, has received acceptance from...

Company

CStone Pharmaceuticals Reports 2023 Interim Financials and Business Milestones

Fineline Cube Aug 16, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced its 2023 interim financial results alongside key business...

Company Deals

HitGen Inc. Partners with Nested Therapeutics for Precision Medicine Research

Fineline Cube Aug 15, 2023

China-based HitGen Inc. (SHA: 688222) has announced a research service agreement with Cambridge, Massachusetts-based precision...

Company Drug

Simcere Pharmaceutical’s Cosela Receives NMPA Review for ES-SCLC Indication

Fineline Cube Aug 15, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Suzhou Leadsynbio Secures Series D Funding to Boost R&D and Market Presence

Fineline Cube Aug 15, 2023

Suzhou Leadsynbio Technology Co., Ltd, a specialist in synthetic biology, has reported raised hundreds of...

Company Drug

SinoMab BioScience Receives NMPA Approval for Phase I Clinical Study of SM17 Asthma Therapy

Fineline Cube Aug 15, 2023

Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that it has received...

Company Deals

Jiangsu Hengrui Pharmaceuticals Strikes Licensing Deal with One Bio Inc. for TSLP-Targeted mAb SHR1905

Fineline Cube Aug 15, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced a significant licensing agreement with...

Posts pagination

1 … 452 453 454 … 630

Recent updates

  • Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership
  • Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label
  • Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development
  • Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter
  • Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Company Drug

Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label

Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Company Drug

Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.